US WorldMeds is a specialty pharmaceutical company located in Louisville, Kentucky. Our mission is to develop, license and commercialize unique and significant pharmaceuticals that address unmet medical needs or overcome the limitations of existing products.
Our product line includes AP-rated Revonto® (dantrolene sodium for injection) for the treatment of malignant hyperthermia, MYOBLOC® (rimabotulinumtoxinB) Injection for the treatment of cervical dystonia in adults and APOKYN® (apomorphine hydrochloride injection) for the acute, intermittent treatment of hypomobility, "off" episodes associated with advanced Parkinson's disease. In addition, another non-narcotic drug product (Lofexidine) for the treatment of opiate withdrawal symptoms is well under development.
1. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439-1446. 2. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431-1438. 3. Pappert EJ, Germanson T; Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;23(4):510-517. 4. Data on file (MYO-026-1207). Malvern, PA: Solstice Neurosciences, Inc; 2007. 5. FDA approval letter. Myobloc for cervical dystonia. December 8, 2000. 6. FDA approval letter. Botox for cervical dystonia. December 21, 2000.